Kiora Pharmaceuticals Net Income
| KPRX Stock | USD 2.15 0.03 1.42% |
As of the 10th of February, Kiora Pharmaceuticals secures the Standard Deviation of 3.21, mean deviation of 2.47, and Risk Adjusted Performance of (0.03). Kiora Pharmaceuticals technical analysis lets you operate historical price patterns with an objective to determine a pattern that forecasts the direction of the firm's future prices.
Kiora Pharmaceuticals Total Revenue |
|
| Last Reported | Projected for Next Year | ||
| Net Income | 3.2 M | 3.4 M | |
| Net Income From Continuing Ops | 4.1 M | 4.3 M | |
| Net Loss | -14.8 M | -15.5 M | |
| Net Income Per Share | 0.84 | 0.88 | |
| Net Income Per E B T | 0.73 | 1.08 |
Kiora | Net Income | Build AI portfolio with Kiora Stock |
The evolution of Net Income for Kiora Pharmaceuticals provides essential context for understanding the company's financial health trajectory. By analyzing this metric's behavior over time, investors can assess whether recent trends align with long-term patterns, and how Kiora Pharmaceuticals compares to historical norms and industry peers.
Latest Kiora Pharmaceuticals' Net Income Growth Pattern
Below is the plot of the Net Income of Kiora Pharmaceuticals over the last few years. Net income is one of the most important fundamental items in finance. It plays a large role in Kiora Pharmaceuticals financial statement analysis. It represents the amount of money remaining after all of Kiora Pharmaceuticals operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue. It is Kiora Pharmaceuticals' Net Income historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Kiora Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported 3.59 M | 10 Years Trend |
|
Net Income |
| Timeline |
Kiora Net Income Regression Statistics
| Arithmetic Mean | (6,654,194) | |
| Geometric Mean | 6,694,607 | |
| Coefficient Of Variation | (90.32) | |
| Mean Deviation | 4,671,158 | |
| Median | (6,861,770) | |
| Standard Deviation | 6,009,935 | |
| Sample Variance | 36.1T | |
| Range | 17.4M | |
| R-Value | 0.23 | |
| Mean Square Error | 36.5T | |
| R-Squared | 0.05 | |
| Significance | 0.38 | |
| Slope | 271,198 | |
| Total Sum of Squares | 577.9T |
Kiora Net Income History
Other Fundumenentals of Kiora Pharmaceuticals
| Net Income From Continuing Ops | ||
| Net Income Applicable To Common Shares | ||
| Net Income Per Share | ||
| Net Income Per E B T |
Kiora Pharmaceuticals Net Income component correlations
Kiora Net Income Driver Correlations
Understanding the fundamental principles of building solid financial models for Kiora Pharmaceuticals is extremely important. It helps to project a fair market value of Kiora Stock properly, considering its historical fundamentals such as Net Income. Since Kiora Pharmaceuticals' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Kiora Pharmaceuticals' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Kiora Pharmaceuticals' interrelated accounts and indicators.
Click cells to compare fundamentals
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Kiora Pharmaceuticals. Expected growth trajectory for Kiora significantly influences the price investors are willing to assign. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Kiora Pharmaceuticals assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Understanding Kiora Pharmaceuticals requires distinguishing between market price and book value, where the latter reflects Kiora's accounting equity. The concept of intrinsic value - what Kiora Pharmaceuticals' is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Market sentiment, economic cycles, and investor behavior can push Kiora Pharmaceuticals' price substantially above or below its fundamental value.
Understanding that Kiora Pharmaceuticals' value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether Kiora Pharmaceuticals represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. In contrast, Kiora Pharmaceuticals' trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.
Kiora Pharmaceuticals 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Kiora Pharmaceuticals' stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Kiora Pharmaceuticals.
| 11/12/2025 |
| 02/10/2026 |
If you would invest 0.00 in Kiora Pharmaceuticals on November 12, 2025 and sell it all today you would earn a total of 0.00 from holding Kiora Pharmaceuticals or generate 0.0% return on investment in Kiora Pharmaceuticals over 90 days. Kiora Pharmaceuticals is related to or competes with Aprea Therapeutics, Biocardia, Acurx Pharmaceuticals, In8bio, Creative Medical, Aptevo Therapeutics, and HCW Biologics. Kiora Pharmaceuticals, Inc., a clinical-stage specialty pharmaceutical company, develops and commercializes therapies fo... More
Kiora Pharmaceuticals Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Kiora Pharmaceuticals' stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Kiora Pharmaceuticals upside and downside potential and time the market with a certain degree of confidence.
| Information Ratio | (0.08) | |||
| Maximum Drawdown | 16.69 | |||
| Value At Risk | (5.19) | |||
| Potential Upside | 4.44 |
Kiora Pharmaceuticals Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Kiora Pharmaceuticals' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Kiora Pharmaceuticals' standard deviation. In reality, there are many statistical measures that can use Kiora Pharmaceuticals historical prices to predict the future Kiora Pharmaceuticals' volatility.| Risk Adjusted Performance | (0.03) | |||
| Jensen Alpha | (0.20) | |||
| Total Risk Alpha | (0.52) | |||
| Treynor Ratio | (0.46) |
Kiora Pharmaceuticals February 10, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | (0.03) | |||
| Market Risk Adjusted Performance | (0.45) | |||
| Mean Deviation | 2.47 | |||
| Coefficient Of Variation | (2,011) | |||
| Standard Deviation | 3.21 | |||
| Variance | 10.31 | |||
| Information Ratio | (0.08) | |||
| Jensen Alpha | (0.20) | |||
| Total Risk Alpha | (0.52) | |||
| Treynor Ratio | (0.46) | |||
| Maximum Drawdown | 16.69 | |||
| Value At Risk | (5.19) | |||
| Potential Upside | 4.44 | |||
| Skewness | 0.6092 | |||
| Kurtosis | 1.5 |
Kiora Pharmaceuticals Backtested Returns
Kiora Pharmaceuticals has Sharpe Ratio of -0.0199, which conveys that the firm had a -0.0199 % return per unit of risk over the last 3 months. Kiora Pharmaceuticals exposes twenty-three different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please verify Kiora Pharmaceuticals' Mean Deviation of 2.47, standard deviation of 3.21, and Risk Adjusted Performance of (0.03) to check out the risk estimate we provide. The company secures a Beta (Market Risk) of 0.37, which conveys possible diversification benefits within a given portfolio. As returns on the market increase, Kiora Pharmaceuticals' returns are expected to increase less than the market. However, during the bear market, the loss of holding Kiora Pharmaceuticals is expected to be smaller as well. At this point, Kiora Pharmaceuticals has a negative expected return of -0.066%. Please make sure to verify Kiora Pharmaceuticals' total risk alpha, kurtosis, as well as the relationship between the Kurtosis and market facilitation index , to decide if Kiora Pharmaceuticals performance from the past will be repeated at some point in the near future.
Auto-correlation | -0.37 |
Poor reverse predictability
Kiora Pharmaceuticals has poor reverse predictability. Overlapping area represents the amount of predictability between Kiora Pharmaceuticals time series from 12th of November 2025 to 27th of December 2025 and 27th of December 2025 to 10th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Kiora Pharmaceuticals price movement. The serial correlation of -0.37 indicates that just about 37.0% of current Kiora Pharmaceuticals price fluctuation can be explain by its past prices.
| Correlation Coefficient | -0.37 | |
| Spearman Rank Test | 0.21 | |
| Residual Average | 0.0 | |
| Price Variance | 0.01 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Kiora Accumulated Other Comprehensive Income
Accumulated Other Comprehensive Income |
|
Based on the recorded statements, Kiora Pharmaceuticals reported net income of 3.59 M. This is 98.95% lower than that of the Biotechnology sector and 94.87% lower than that of the Health Care industry. The net income for all United States stocks is 99.37% higher than that of the company.
Kiora Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Kiora Pharmaceuticals' direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Kiora Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Kiora Pharmaceuticals by comparing valuation metrics of similar companies.Kiora Pharmaceuticals is currently under evaluation in net income category among its peers.
Kiora Pharmaceuticals Current Valuation Drivers
We derive many important indicators used in calculating different scores of Kiora Pharmaceuticals from analyzing Kiora Pharmaceuticals' financial statements. These drivers represent accounts that assess Kiora Pharmaceuticals' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Kiora Pharmaceuticals' important valuation drivers and their relationship over time.
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 (projected) | ||
| Market Cap | 131.1M | 22.6M | 2.5M | 12.8M | 14.7M | 14.0M | |
| Enterprise Value | 123.4M | 16.7M | 180.8K | 9.0M | 10.4M | 9.9M |
Kiora Pharmaceuticals ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Kiora Pharmaceuticals' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Kiora Pharmaceuticals' managers, analysts, and investors.Environmental | Governance | Social |
Kiora Pharmaceuticals Institutional Holders
Institutional Holdings refers to the ownership stake in Kiora Pharmaceuticals that is held by large financial organizations, pension funds or endowments. Institutions may hold large blocks of Kiora Pharmaceuticals' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Kiora Pharmaceuticals' value.| Shares | Goss Wealth Management Llc | 2025-06-30 | 22.0 | Bank Of America Corp | 2025-06-30 | 21.0 | Advisor Group Holdings, Inc. | 2025-06-30 | 2.0 | Activest Wealth Management | 2025-06-30 | 2.0 | Sabby Management Llc | 2025-06-30 | 0.0 | Citadel Advisors Llc | 2025-06-30 | 0.0 | Morgan Stanley - Brokerage Accounts | 2025-06-30 | 0.0 | U.s. Bancorp | 2025-03-31 | 0.0 | Rosalind Advisors, Inc. | 2025-06-30 | 0.0 | Aigh Capital Management, Llc | 2025-06-30 | 216.3 K | Nantahala Capital Management, Llc | 2025-06-30 | 211.1 K |
Kiora Fundamentals
| Return On Equity | -0.33 | ||||
| Return On Asset | -0.17 | ||||
| Current Valuation | (10.99 M) | ||||
| Shares Outstanding | 3.68 M | ||||
| Shares Owned By Insiders | 2.98 % | ||||
| Shares Owned By Institutions | 19.92 % | ||||
| Number Of Shares Shorted | 25.74 K | ||||
| Price To Book | 0.36 X | ||||
| Price To Sales | 363.74 X | ||||
| Revenue | 16 M | ||||
| Gross Profit | (3.72 M) | ||||
| EBITDA | 5.7 M | ||||
| Net Income | 3.59 M | ||||
| Cash And Equivalents | 2.43 M | ||||
| Cash Per Share | 2.64 X | ||||
| Total Debt | 57.17 K | ||||
| Debt To Equity | 0.02 % | ||||
| Current Ratio | 1.53 X | ||||
| Book Value Per Share | 6.53 X | ||||
| Cash Flow From Operations | 8.56 M | ||||
| Short Ratio | 0.86 X | ||||
| Earnings Per Share | (2.19) X | ||||
| Target Price | 12.0 | ||||
| Number Of Employees | 12 | ||||
| Beta | -0.81 | ||||
| Market Capitalization | 7.91 M | ||||
| Total Asset | 36.48 M | ||||
| Retained Earnings | (143.38 M) | ||||
| Working Capital | 23.7 M | ||||
| Net Asset | 36.48 M |
About Kiora Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Kiora Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Kiora Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Kiora Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Kiora Stock Analysis
When running Kiora Pharmaceuticals' price analysis, check to measure Kiora Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Kiora Pharmaceuticals is operating at the current time. Most of Kiora Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Kiora Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Kiora Pharmaceuticals' price. Additionally, you may evaluate how the addition of Kiora Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.